TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02742870

Intervention type: OTHER
Intervention: Correlation of MRI results with clinical characteristics of the adnexal mass
Description: Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.~The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up.
Study: NCT02047513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perioperative nab-paclitaxel/gemcitabine
Description: 2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant nab-paclitaxel/gemcitabine
Description: Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
Study: NCT03235570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib at the protocol-defined dose administered once daily.
Study: NCT04436224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Intravenous analgesia using hydromorphone in ICU patients with non-mechanical ventilation(NS 40ML+ hydromorphone 10mg ，IV-Pump)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butorphanol
Description: Intravenous analgesia using butorphanol in ICU patients with non-mechanical ventilation(NS 40ML+ butorphanol 10mg，IV-Pump)
Study: NCT03075462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib either at 40,60,80mg twice daily,capsule oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib at 250mg once daily, tablet oral
Study: NCT02641236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin-polymyxin B
Study: NCT03868007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-RIC
Description: The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study: NCT00069576

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self blood glucose monitoring
Study: NCT02304536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH
Description: 70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian drilling
Description: 70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
Study: NCT01094717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin 25Mg Oral Capsule
Description: Acitretin 25 mg oral daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin 25Mg Oral Capsule
Description: Acitretin 25 mg oral daily for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser
Description: Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser
Description: Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% Gel,Top
Description: Topical tazarotene 0.1% gel was applied daily to active lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% Gel,Top
Description: Topical tazarotene 0.1% gel was applied daily to active lesions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham excimer laser
Description: Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham excimer laser
Description: Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
Study: NCT03112902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
Study: NCT03229915

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive processing therapy
Description: Group therapy for PTSD patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive processing therapy
Description: Group therapy for PTSD patients
Study: NCT03112902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
Study: NCT04263337

Intervention type: DRUG
Group type: OTHER
Intervention: [11C] PiB
Description: Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study: NCT04113889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)
Description: 72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin, pioglitazone and placebo
Description: 72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
Study: NCT04159259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fiber diet
Description: Participants will be provided with a low fiber diet in the form of packed out meals and snacks for 24 days in total (days 5-14 and days 36-49)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea Fiber Bar
Description: Participants will be provided with a low fiber diet plus 1-3 daily pea fiber bars from days 15-35

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fiber diet
Description: Participants will return to the low fiber diet for days 36-49- this phase is the same as phase 1.
Study: NCT02332668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT01733316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystagon®
Study: NCT03782961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium lactate and combination of polymers
Description: sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium lactate and combination of polymers
Description: sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)
Study: NCT04663204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Target dose of 400 mg daily
Study: NCT03334630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiamondTemp Ablation catheter
Description: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TactiCath Quartz Ablation catheter
Description: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
Study: NCT02460458

Intervention type: DRUG
Intervention: Von Willebrand Factor
Description: Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
Study: NCT02059408

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screen-Educate
Description: Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screen-Educate
Description: Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screen-Educate and Intensify Treatment
Description: This arm adds option of a pharmacist. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys \<45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
Study: NCT04690933

Intervention type: OTHER
Intervention: Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients
Description: Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
Study: NCT02626533

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
Study: NCT03602508

Intervention type: DRUG
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Intervention: solifenacin
Description: oral

Intervention type: DRUG
Intervention: darifenacin
Description: oral

Intervention type: DRUG
Intervention: imidafenacin
Description: oral

Intervention type: DRUG
Intervention: tolterodine
Description: oral

Intervention type: DRUG
Intervention: oxybutynin
Description: oral

Intervention type: DRUG
Intervention: trospium
Description: oral

Intervention type: DRUG
Intervention: fesoterodine
Description: oral

Intervention type: DRUG
Intervention: propiverine
Description: oral
Study: NCT04021108

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab 240 MG
Description: Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
Study: NCT00249860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
Study: NCT04021108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 MG
Description: Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
Study: NCT00249860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin plus Interferon-beta-1a
Description: Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
Study: NCT03837860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Placebo
Description: Oxycodone 20 mg plus placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Risperidone
Description: Oxycodone (20mg) plus Risperidone (2 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Ziprasidone
Description: Oxycodone (20mg) plus Ziprasidone (80 mg)
Study: NCT04995887

Intervention type: DEVICE
Intervention: Jada® System
Description: The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.

Intervention type: DEVICE
Intervention: Jada® System
Description: The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.

Intervention type: DEVICE
Intervention: Jada® System
Description: The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.

Intervention type: DEVICE
Intervention: Jada® System
Description: The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
Study: NCT04173962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: administered 1 week prior to a laboratory-induced stress

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: administered 1 week prior to a laboratory-induced stress
Study: NCT01547741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT01090492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
Study: NCT03216109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly telephone symptom assessment
Description: Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
Study: NCT00368316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella conjugate vaccines
Description: Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella conjugate vaccines
Description: Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
Study: NCT00932217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: subcutaneous filgrastim administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenograstim
Description: subcutaneous lenograstim administration
Study: NCT01856439

Intervention type: DRUG
Group type: OTHER
Intervention: ProSavin
Description: Long term follow up of patients who received ProSavin in a previous study